As part of its quarterly cleaning, Eli Lilly removed a few trials from its pipeline, including late-stage studies of approved cancer drug Verzenio and its Boehringer Ingelheim-partnered drug Jardiance.
The Indianapolis-based pharma giant also removed a Phase 2 trial of a gene therapy it got through the $1 billion-plus acquisition of Prevail Therapeutics a few years ago. Also out the door is an undisclosed Phase 1 immunology asset, per the company’s first-quarter earnings presentation.
The moves come as Lilly ramped up its R&D spending in the first quarter to $2.52 billion, a 27% increase. It’s also still working through supply hurdles for its diabetes and obesity medications. The potential of the drugs, known as Mounjaro and Zepbound, have propelled Lilly to the largest pharmaceutical company in the world by market capitalization.
Lilly’s share price $LLY was up nearly 7% in Tuesday morning trading.
On the Verzenio front, Lilly said it culled the Phase 3 CYCLONE-3 trial of the cancer drug in patients with hormone sensitive prostate cancer due to futility. The company said it took an approximately $75 million charge in the first quarter due to the prostate cancer program termination.
The move adds to a recent string of disappointments for Verzenio. Earlier this year, Lilly also scrapped a late-stage study of the medicine in patients with castration-resistant prostate cancer after it failed to improve progression-free survival. The CDK4/6 inhibitor also missed an overall survival endpoint in advanced breast cancer last December.
Meanwhile, Lilly removed a Phase 3 test of its type 2 diabetes and heart failure drug Jardiance, which it markets with Boehringer Ingelheim. The drug failed the EMPACT-MI study earlier this month, Boehringer reported. Jardiance was not better than placebo at lowering the chances of going to the hospital due to heart failure or all-cause mortality, with just a 10% relative risk reduction shown in the study, Boehringer said April 6.
For the Prevail-acquired GBA1 gene therapy, Lilly said it pulled a Phase 2 study testing the asset in patients with Gaucher disease type 2. The fatal disease disrupts a baby’s brain and causes an enlarged liver and spleen, among other impacts.
Lilly is still testing the gene therapy, known as LY3884961 (formerly PR001), in patients with Gaucher type 1 and Parkinson’s disease with at least one GBA1 mutation. The PROCEED and PROPEL trials, respectively, are still recruiting, as of recent updates to their ClinicalTrials.gov listing.
https://endpts.com/lilly-scraps-trials-of-verzenio-jardiance-and-a-gene-therapy-from-prevail/
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
NeuExcell Therapeutics Unveils Breakthrough in Stroke Treatment at ASGCT 2024
In a groundbreaking development, NeuExcell Therapeutics has revealed a significant breakthrough in its NXL-001 product for stroke treatment. The announcement was made at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, where the company...
Unraveling CRISPR Precision: BreakTag Illuminates Pathways to Improved Gene Editing
Introduction:The quest for precision in CRISPR-Cas9 gene editing takes a significant leap forward with the development of BreakTag, a method devised to enhance our understanding of DNA double-strand breaks (DSBs) induced by Cas9. This breakthrough, detailed in a...
Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
–Supplemental New Drug Application (sNDA) submission based on Phase 3 study of vibegron 75mg (GEMTESA) demonstrating statistically significant reductions in daily micturition and urgency episodes– –If approved, vibegron will be the first and only beta-3 agonist for...
Herpes cure with gene editing makes progress in laboratory studies
Herpes simplex virus. Credit: CDCResearchers at Fred Hutch Cancer Center have found in pre-clinical studies that an experimental gene therapy for genital and oral herpes removed 90% or more of the infection and suppressed how much virus can be released from an...
Related Services